MD Anderson研究人员创建了TmS,这是一个新的生物标志,通过分析肿瘤基因活动和微观环境,更好地预测三联阴性乳腺癌的化学反应,显示出进行个性化治疗的前景。 MD Anderson researchers created TmS, a new biomarker that better predicts chemo response in triple-negative breast cancer by analyzing tumor gene activity and microenvironment, showing promise for personalized treatment.

MD Anderson癌症中心的研究人员开发了一个新的生物标志(TmS),通过计算肿瘤及其微环境内的基因表达方式变化,改进了对三联阴性乳腺癌的化疗反应的预测。 Researchers at MD Anderson Cancer Center have developed a new biomarker, TmS, which improves predictions of chemotherapy response in triple-negative breast cancer by accounting for gene expression changes within tumors and their microenvironments. 在对575名不同族裔的病人进行测试后,TMS在区分高预测群体和低预测群体方面成绩优于现有模式,并揭示了西亚和亚洲病人之间肿瘤微环境的差异,表明有进行个性化治疗的潜力。 Tested on 575 ethnically diverse patients, TmS outperformed existing models in distinguishing high- and low-prognosis groups and revealed differences in tumor microenvironments between Western and Asian patients, suggesting potential for personalized treatments. 该工具整合了肿瘤细胞比率和RNA活动动态,为病人分层提供了更准确、更便捷的方法,尽管在临床使用前还需要进一步验证。 The tool integrates tumor cell ratios and RNA activity dynamics, offering a more accurate, accessible method for patient stratification, though further validation is needed before clinical use.